SOPHiA GENETICS (NASDAQ:SOPH) Sees Strong Trading Volume – Here’s What Happened

SOPHiA GENETICS SA (NASDAQ:SOPH) saw unusually-strong trading volume on Monday . Approximately 110,773 shares changed hands during mid-day trading, a decline of 42% from the previous session’s volume of 191,681 shares.The stock last traded at $6.2450 and had previously closed at $5.87.

Analyst Ratings Changes

SOPH has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday. HC Wainwright assumed coverage on SOPHiA GENETICS in a research report on Monday. They issued a “buy” rating and a $12.00 target price for the company. Finally, BTIG Research restated a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, SOPHiA GENETICS presently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

SOPHiA GENETICS Trading Up 2.7%

The stock has a market capitalization of $545.28 million, a price-to-earnings ratio of -12.50 and a beta of 0.96. The company has a fifty day moving average of $5.30 and a two-hundred day moving average of $5.05. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The firm had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Insider Buying and Selling at SOPHiA GENETICS

In other news, insider Zhenyu Xu sold 7,393 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $5.17, for a total value of $38,221.81. Following the completion of the transaction, the insider owned 614,887 shares in the company, valued at $3,178,965.79. This trade represents a 1.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ross Muken sold 9,838 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $5.22, for a total transaction of $51,354.36. Following the completion of the transaction, the chief executive officer directly owned 670,651 shares of the company’s stock, valued at approximately $3,500,798.22. This trade represents a 1.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 176,711 shares of company stock worth $959,913. Company insiders own 4.88% of the company’s stock.

Hedge Funds Weigh In On SOPHiA GENETICS

Several hedge funds have recently bought and sold shares of SOPH. First Dallas Securities Inc. purchased a new stake in shares of SOPHiA GENETICS in the first quarter valued at $50,000. Squarepoint Ops LLC purchased a new stake in SOPHiA GENETICS during the 3rd quarter worth about $49,000. Perkins Capital Management Inc. purchased a new stake in SOPHiA GENETICS during the 4th quarter worth about $49,000. Quadrature Capital Ltd acquired a new position in SOPHiA GENETICS in the 4th quarter valued at about $54,000. Finally, XTX Topco Ltd acquired a new position in SOPHiA GENETICS in the 4th quarter valued at about $55,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.